Variables | RAS | LAS | P |
---|---|---|---|
Total clinical cases, n | 200 | 486 | Â |
Gender (male, %) | 121 (60.5) | 302 (62.1) | 0.688 |
Average age (mean, SD) | 58.4±11.8 | 59.8±11.5 | 0.149 |
Body mass index (mean, SD) | 23.1±3.1 | 22.9±3.5 | 0.402 |
ASA classification | |||
 I(%) | 26 (13) | 52 (10.7) | 0.335 |
 II(%) | 134 (67) | 353 (72.6) | |
 III(%) | 40 (20) | 81 (16.7) | |
NRS2002 score (median, IQR) | 2 (2,3) | 2 (2,3) | 0.408 |
Diabetes (yes, %) | 26 (13) | 54 (11.1) | 0.484 |
Level of hemoglobin(g/L, mean, SD) | 130.9±15.4 | 129.5±15.3 | 0.263 |
Level of plasma albumin(g/L, mean, SD) | 43.2±7.1 | 42.7±3.6 | 0.163 |
Level of CEA (≥5 ng/ml, %) | 49 (24.5) | 154 (31.7) | 0.061 |
Level of CA199 (≥36 u/ml, %) | 18 (9) | 58 (11.9) | 0.266 |
Distance from anal edge (cm, mean, SD) | 5.06±0.84 | 5.66±0.53 | <0.0001 |
MRI cT stage, N (%) | |||
 T1 (%) | 26 (13) | 59 (12.1) | 0.738 |
 T2 (%) | 117 (58.5) | 274 (56.4) | |
 T3 (%) | 57 (28.5) | 153 (31.5) | |
MRI cN stage, N (%) | |||
 N0 (%) | 126 (63) | 336 (69.1) | 0.297 |
 N1 (%) | 43 (21.5) | 87 (17.9) | |
 N2 (%) | 31 (15.5) | 63 (13) | |
MRI cTNM stage, N (%) | 0.464 | ||
 I(%) | 99 (49.5) | 250 (51.4) | |
 II(%) | 39 (19.5) | 107 (22) | |
 III(%) | 62 (31) | 129 (26.5) | |
Neoadjuvant chemoradiotherapy (%) | 21 (10.5) | 43 (8.8) | 0.441 |
Total hospitalization costs (¥), mean (SD) | 53,922±14290 | 48,522±17466 | <0.0001 |